<DOC>
	<DOC>NCT01165138</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.</brief_summary>
	<brief_title>Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatients at least 12 years of age Male and female; female subjects of childbearing potential must be willing to use birth control Prebronchodilator FEV1 of 4090% predicted normal Reversibility FEV1 of at least 12% and 200mL Current asthma therapy includes inhaled corticosteroid use for at least 12 weeks prior to first visit History of lifethreatening asthma during last 10 years Respiratory infection or oral candidiasis Asthma exacerbation requiring oral corticosteroids or that required overnight hospitalisation requiring additional asthma treatment Uncontrolled disease or clinical abnormality Allergies to study drugs or the excipients Taking another investigational medication or prohibited medication Night shift workers Current smokers or subjects with a smoking history of at least 10 pack years</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>Vilanterol</keyword>
	<keyword>Asthma</keyword>
	<keyword>Fluticasone Furoate</keyword>
</DOC>